一个双盲,随机,安慰剂受控的试验,在帕金森病中使用乌尔索多西胆酸 (UDCA)
Thomas Payne1, Matthew Appleby2,3, Ellen Buckley4
1Sheffield Institute for Translational Neuroscience, The University of Sheffield, Sheffield, UK.
概括
乌尔索多西胆酸 (UDCA) 对于帕金森病 (PD) 患者来说是安全的,显示出改善线粒体功能和步态的潜力. 需要进一步的研究来确认其在PD中的疾病修饰作用.
科学领域:
- 神经科学是一个神经科学.
- 线粒体生物学 线粒体生物学
- 药理学 药理学是指药理学的学科.
背景情况:
- 线粒体功能障碍是帕金森病 (PD) 发病的一个关键因素.
- 在临床前模型中, Ursodeoxycholic 酸 (UDCA) 在 PD 中拯救线粒体功能方面表现有前途.
- 在PD患者中,UDCA的潜在神经保护作用需要进行临床研究.
研究的目的:
- 评估PD患者高剂量UDCA的安全性和耐受性.
- 通过31磁共振光谱 (31P-MRS) 评估UDCA在中脑中的目标参与.
- 探索UDCA对PD运动进展的影响,包括步态.
主要方法:
- 一个II期,随机,双盲,安慰剂对照试验 (UP研究) 涉及30名PD参与者.
- 参与者接受了UDCA (30毫克/公斤每天) 或安慰剂48周.
- 结果包括安全性评估,31P-MRS用于中脑位参与,以及运动/行走评估 (MDS-UPDRS-III,运动传感器).
主要成果:
- 发现UDCA是安全的,耐受性很好,轻微的胃肠道事件是最常见的不良事件.
- 中脑31P-MRS在UDCA组中显示了改善的ATP水解,由增加的Gibbs自由能量和无机酸盐证明.
- 虽然基于传感器的步态分析表明了节奏的潜在改善,但MDS-UPDRS-III没有检测到组之间的显著差异.
结论:
- 高剂量的UDCA在帕金森病的早期阶段是安全的,并且耐受性良好.
- 在PD中脑中,UDCA显示了改善线粒体功能的潜力.
- 需要进行更大规模的临床试验,以验证UDCA在PD中的疾病修饰能力.
相关概念视频
01:24Parkinson's Disease: Treatment
308
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
308
01:15Parkinson's Disease: Overview
614
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
614
01:22Alzheimer's Disease: Treatment
226
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
226
01:11Clinical Trials: Overview
3.1K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
3.1K
01:11Blinding
2.5K
Blinding is a commonly used method of not telling participants which treatment a subject is receiving. Blinding is a critical part of a randomized control trial or RCT. It reduces the bias that affects the results. In an RCT, blinding is used in the form of a placebo. A placebo effect occurs when untreated subjects falsely believe they have received the treatment and report improved symptoms. A placebo or a dummy treatment is administered to subjects to negate the bias caused by such an effect.
2.5K
01:11Direct-Acting Cholinergic Agonists: Therapeutic Uses
797
Direct-acting cholinergic agonists have many therapeutic uses in various medical fields. Choline esters, including acetylcholine, have limited clinical utility due to their non-selectivity and short duration of action. Still, acetylcholine and carbachol are applied topically during ophthalmologic surgery to induce miosis. Pilocarpine, a muscarinic and ganglionic stimulator, effectively treats open-angle glaucoma and alleviates xerostomia and dry mouth caused by radiotherapy or Sjögren...
797